Amgen Astellas BioPharma

Amgen Astellas BioPharma was a joint venture established in 2013 between Amgen and Astellas Pharma to develop and commercialize Amgen's innovative pipeline in the Japanese market. Headquartered in Tokyo, the company focused on therapeutic areas including oncology, cardiovascular disease, and bone health. Key products launched through the partnership include Repatha for high cholesterol and Blincyto for leukemia. In 2020, Amgen acquired Astellas's remaining stake, transitioning the entity into a wholly-owned subsidiary known as Amgen K.K. The company continues to operate as Amgen's primary presence in Japan, managing a robust portfolio of biologics and small molecules.